<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507555</url>
  </required_header>
  <id_info>
    <org_study_id>PrePGx_ex20Mikoteit</org_study_id>
    <nct_id>NCT04507555</nct_id>
  </id_info>
  <brief_title>Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy</brief_title>
  <acronym>PrePGx</acronym>
  <official_title>Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Thorsten Mikoteit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Psychiatrische Dienste Solothurn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study at the Solothurn Psychiatric Clinic, the investigators compare the&#xD;
      effectiveness and tolerability of antidepressant pharmacotherapy in three groups. In the&#xD;
      intervention group, the physician selects and doses the medication for depression based on a&#xD;
      pharmacogenetic examination conducted by a clinical pharmacist. In the standard group, the&#xD;
      treating physician selects and doses the antidepressant drug without the support of genetic&#xD;
      testing, in accordance with current standard practice. If after the first week of&#xD;
      hopsitalization no adjustment to a new antidepressant is necessary, the investigators will&#xD;
      monitor the progress of these patients until they leave the clinic in an observational arm.&#xD;
      The drugs used are all approved in Switzerland for the treatment of depression.&#xD;
      Classification into the intervention or standard group is made randomly after the first week&#xD;
      of hospitalisation, if the treating physician deems it necessary to change or readjust the&#xD;
      antidepressant pharmacotherapy. The probability of allocation to one of the two study groups&#xD;
      is 50%. All study participants will be hospitalized for at least five weeks and monitored&#xD;
      until they leave the clinic. In total, it is planned to include and examine 95 patients each&#xD;
      into the intervention and standard group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of response to the antidepressant therapy at the end of week 4</measure>
    <time_frame>28 days</time_frame>
    <description>response is determined as a reduction in the Hamilton Depression (HAM-D17) Scale score of at least 50 % of the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>28 days</time_frame>
    <description>time span from start of antidepressant pharmacotherapy until first assessed response (= HAM-D17 reduction of at least 50 % compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate</measure>
    <time_frame>28 days</time_frame>
    <description>17 item Hamilton rating scale for Depression (HAM-D17) score ≤ 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall change in 17 item Hamilton rating scale for Depression (HAM-D17) from baseline to week 4</measure>
    <time_frame>28 days</time_frame>
    <description>minimum value: 0, maximum value: 52 ; higher scores mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time till discharge</measure>
    <time_frame>assessed up to 3 month</time_frame>
    <description>time span from admission (randomization) to discharge from inpatient treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient depression self-rating</measure>
    <time_frame>28 days</time_frame>
    <description>two weekly assessment with Beck's Depression Inventory questionnaire (BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect measure (self-rated frequency, intensity and burden of side effects, FIBSER score)</measure>
    <time_frame>28 days</time_frame>
    <description>weekly assessment, minimum value: 0, maximum value: 18 ; higher scores mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related to antidepressant pharmacotherapy</measure>
    <time_frame>28 days</time_frame>
    <description>severity grading ≥ 2 (using CTCAE version 5.0) and causality to antidepressant pharmacotherapy assessed as possible, probable or definite</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing</intervention_name>
    <description>The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.&#xD;
This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard care antidepressant selection and dosing</intervention_name>
    <description>Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Diagnosis unipolar moderate or severe depressive episode or recurrent depressive&#xD;
             disorder (ICD10: F32.1/32.2/33.1/33.2)&#xD;
&#xD;
          -  HAM-D17 ≥ 17&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute suicide risk&#xD;
&#xD;
          -  Psychotic symptomatology&#xD;
&#xD;
          -  Other acute serious psychiatric disorder other than depression&#xD;
&#xD;
          -  Excessive consumption of alcohol and/or drugs&#xD;
&#xD;
          -  Severe acute - or severe chronic somatic diseases&#xD;
&#xD;
          -  Pregnant / lactating women&#xD;
&#xD;
          -  Under current treatment with fluoxetine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten Mikoteit, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatrische Dienste Solothurn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Céline Stäuble, MSc</last_name>
    <phone>+41 61 207 61 78</phone>
    <email>celine.staeuble@unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Psychiatrische Dienste Solothurn</name>
      <address>
        <city>Solothurn</city>
        <zip>4503</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Mikoteit, PD Dr. med.</last_name>
      <phone>+41 32 627 11 11</phone>
      <email>thorsten.mikoteit@spital.so.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Thorsten Mikoteit</investigator_full_name>
    <investigator_title>Deputy Head Physician Division Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

